Jpmorgan Chase & CO Morpho Sys Ag Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.72 - $8.6 $7,956 - $10,182	1,184 Added 3.07%	39,693 $266,000
Q2 2023 Aug 11, 2023	BUY	$3.95 - $7.74 $152,110 - $298,059	38,509 New	38,509 $287,000
Q2 2022 Aug 11, 2022	SELL	$4.51 - $7.39 $2,845 - $4,663	-631 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$5.87 - $9.73 $3,703 - $6,139	631 New	631 $4,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.